Almost a year after two historic approvals, Pfizer is pulling a sickle cell disease treatment from the market, and the ...
Agios Pharmaceuticals (NASDAQ:AGIO) is scheduled to announce Q3 earnings results on Thursday, October 31st, before market open. The consensus EPS Estimate is $7.91 and the consensus Revenue Estimate ...
We think the market is overly bearish about Pfizer’s ability to right the ship, and we see shares as undervalued.
Despite today's fall in Pfizer's share price, it beat my and Wall Street analysts' expectations for Q3 by a large margin. See ...
The company’s updated guidance for revenue includes approximately $10.5B in anticipated revenues for Comirnaty and Paxlovid, ...
Zacks.com on MSN7d
Pfizer's Q3 Earnings Beat, Paxlovid Drives Sales Guidance IncreasePfizer PFE reported third-quarter 2024 adjusted earnings per share of $1.06, which crushed the Zacks Consensus Estimate of 64 ...
Pfizer (PFE) stock gained after the company beat estimates with its Q3 2024 financials and raised its full-year guidance ...
As therapies for rare and neurological diseases earn accelerated approval, experts laud the program’s intent while remaining ...
Yet another therapy with FDA accelerated approval suffers a setback; Sage’s tough year continues; Sanofi drops $326 million ...
EDT Cathie Wood’s ARK Investment bought 47.8K shares of Crispr Therapeutics (CRSP) today Published first on TheFly – the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback